Renzapride: Difference between revisions
Jump to navigation
Jump to search
m (Protected "Renzapride": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite))) |
(No difference)
|
Latest revision as of 18:20, 27 September 2011
Renzapride is a full serotonin 5-HT4 receptor agonist, partial serotonin 5-HT3 receptor antagonist.
Clinical Uses
Renzapride is currently in Phase III clinical development in the United States for the treatment of constipation-predominant irritable bowel syndrome (IBS-C). It is also potentially effective for irritable bowel syndrome with alternating stool pattern (IBS-A). It is being developed by Alizyme of the UK.